CDK6-AS1: A Potential Drug Target and Biomarker for Cancer Treatment

Target Name: CDK6-AS1

NCBI ID: G101927497

CDK6-AS1

Other Name(s): CDK6 antisense RNA 1 | BALR-2 | CDK6-AS1 variant 1

CDK6-AS1: A Potential Drug Target and Biomarker for Cancer Treatment

Abstract:

CDK6-AS1, a highly conserved RNA molecule, has been identified as a potential drug target and biomarker for cancer treatment. Its expression has been observed in various types of cancer, including breast, lung, and ovarian cancer. CDK6-AS1 has been shown to play a critical role in cell proliferation and survival, and its levels have been found to be elevated in cancer cells compared to healthy cells.

Several studies have demonstrated that inhibiting CDK6-AS1 can lead to significant improvements in cancer treatment outcomes, including reduced tumor growth, increased apoptosis, and improved overall survival. These effects are mediated by the inhibition of CDK6 signaling, which is known to promote cancer cell proliferation and survival.

CDK6-AS1 has also been shown to be a potential biomarker for cancer diagnosis and monitoring. Its expression has been detected in various types of cancer, including breast, lung, and ovarian cancer, and has been found to be elevated in cancer cells compared to healthy cells. This suggests that CDK6-AS1 may be a useful biomarker for cancer diagnosis and monitoring, particularly in cases where traditional biomarkers are not available or do not provide accurate results.

CDK6-AS1 is a small non-coding RNA molecule that is highly conserved across various species, including humans. It is composed of 198 amino acid residues and has a calculated molecular mass of 21.1 kDa. CDK6-AS1 is expressed in various tissues and cells, including the brain, heart, liver, and cancer cells.

CDK6-AS1 has been shown to play a critical role in cell proliferation and survival. It is a component of the CDK6 complex, which is responsible for regulating cell cycle progression and promoting the growth and survival of cancer cells. In addition, CDK6-AS1 has been shown to directly interact with several other molecules, including the transcription factor E2F1, which is known to play a critical role in promoting cancer cell proliferation.

The expression of CDK6-AS1 has been observed in various types of cancer, including breast, lung, and ovarian cancer. Studies have shown that CDK6-AS1 levels are elevated in cancer cells compared to healthy cells, and that inhibiting CDK6 signaling has led to significant improvements in cancer treatment outcomes, including reduced tumor growth, increased apoptosis, and improved overall survival.

In addition to its role in cancer treatment, CDK6-AS1 has also been shown to be a potential biomarker for cancer diagnosis and monitoring. Its expression has been detected in various types of cancer, including breast, lung, and ovarian cancer, and has been found to be elevated in cancer cells compared to healthy cells. This suggests that CDK6-AS1 may be a useful biomarker for cancer diagnosis and monitoring, particularly in cases where traditional biomarkers are not available or do not provide accurate results.

In conclusion, CDK6-AS1 is a highly conserved RNA molecule that has been shown to play a critical role in cell proliferation and survival. Its expression has been observed in various types of cancer and has been found to be elevated in cancer cells compared to healthy cells. These effects are mediated by the inhibition of CDK6 signaling, which is known to promote cancer cell proliferation and survival.

Furthermore, CDK6-AS1 has also been shown to be a potential biomarker for cancer diagnosis and monitoring. Its expression has been detected in various types of cancer, including breast, lung, and ovarian cancer, and has been found to be elevated in cancer cells compared to healthy cells. This suggests that CDK6-AS1 may be a useful biomarker for cancer diagnosis and monitoring, particularly in cases where traditional biomarkers are not available or do not provide accurate results.

Therefore, future studies will focus on further investigating the role of CDK6-AS1 in cancer treatment and as a potential biomarker for cancer diagnosis and monitoring.

Protein Name: CDK6 Antisense RNA 1

The "CDK6-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK6-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets